Novo Nordisk Inks Collab with Kallyope for Gut–Brain Axis Drug Discovery

Novo Nordisk has announced a drug discovery collaboration with New York–based Kallyope to develop peptide therapeutics to treat obesity and diabetes.Under the terms of the agreement, the value of which was not disclosed, Kallyope will receive an up-front payment and research support in exchange for granting a option for Novo Nordisk to license exclusive worldwide rights to develop and commercialize up to six products discovered in the collaboration. Kallyope will receive a license fee if N